Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BIOT Named Authorized Representative for IN01 Cancer Immunotherapy in Japan and China

September 30, 2026

Instinct Bio Receives Nasdaq Notifications Regarding Minimum Bid Requirement and Minimum Market Value of Listed Securities and Publicly Held Shares

Performance

52-Week Range 99.6% below 52-week high

0.2046

0.2052W Low 50.0052W High

1 Week 33.4% below 1-week high

0.201W Low 0.311W High

Instinct Bio Technical Company Holdings Inc. - Common stock (BIOT) traded between $0.20 and $50.00 over the past 52 weeks and last traded at $0.20, 99.6% below its 52-week high. Over the past week it ranged between $0.20 and $0.31.

Past 12 Months

-10.4%

-53.0%

-98.7%

1W -$0.02

1M -$0.23

3M -$15.30

6M -$15.30

YTD -$15.30

1Y -$15.30

BIOT was -98.7% over the past year, -98.7% over six months, -98.7% year to date, -10.4% in the last week.

12 Months vs Market

BIOT

-98.7%

DIA

+13.3%

SPY

+14.4%

QQQ

+16.3%

IWM

+13.7%

Over the past 12 months BIOT returned -98.7% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity

652.5K

489.4K

707.1K

YTD

707.1K

BIOT's 3-month average daily volume is 707.1K.

More News

September 15, 2026

INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives

September 04, 2026

From Instinct Bio Technical Company Holdings Inc.

Via GlobeNewswire

Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia

August 10, 2026

From Instinct Bio Technical Company Holdings Inc.

Via GlobeNewswire

Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives

July 30, 2026

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

August 01, 2022

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 03, 2022

Via InvestorPlace

May 18, 2022

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

May 16, 2022

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

April 04, 2022

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

March 24, 2022

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

January 12, 2022